BioSpace News Archive

Nonprofit addiction treatment leader says bill advances several key priorities in effort to confront nation’s most urgent public health issue

Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced topline positive safety and efficacy data from the second dose cohort and positive longer-term data from the first dose cohort of the ongoing Phase 1/2 study of DTX301.

Scientists at Cold Spring Harbor Laboratory (CSHL) have determined one of the ways in which cancers in remission can spring back into action.

AMN Healthcare has again been recognized by The Joint Commission for its commitment to placement of high-quality clinicians throughout the healthcare industry.

Natural Products Canada and BioAlberta have joined forces to help companies, investors, researchers and others participate in the expanding opportunities in naturally-derived products and solutions.

Report’s recommendations aim to make Canada a top-three global hub for health and biosciences and a top-five performer in Commonwealth Fund health system rankings

Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Alnylam securities between February 15, 2018 through September 12, 2018, both dates inclusive

CEO David Cordani’s Leadership Team Will “Drive Improvements in Affordability, Choice and Quality for Customers and Clients; Sustained, Attractive Return for Shareholders”

Wireless storage and security for critical medications, with automated logging of transactions and inventory reporting on-demand